Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Humanin
Also known as: HN, HNG (S14G-humanin)
Humanin is a 24-amino acid peptide encoded in the mitochondrial genome, making it one of the first identified mitochondria-derived peptides (MDPs). It was discovered in 2001 from surviving neurons of Alzheimer's disease brains. It demonstrates broad cytoprotective effects in preclinical models of neurodegeneration, cardiovascular disease, and metabolic disorders. Circulating humanin levels decline with age. No therapeutic clinical trials have been completed.
Risk Level
Medium RiskDifficulty
Advanced| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds and activates a tripartite receptor complex (CNTFR/WSX-1/gp130), triggering STAT3 signaling and pro-survival pathways. Also binds IGFBP-3 to modulate IGF signaling and interacts with BAX to prevent mitochondrial apoptosis. Reduces ER stress, oxidative damage, and inflammatory signaling through multiple complementary mechanisms.
Dosing Research
No established human dosing. Research uses the potent analog HNG (S14G-humanin). Animal studies use doses in the microgram/kg range intraperitoneally. Underground protocols are extremely rare and dosing is purely speculative. The native peptide has poor stability in vivo.
Side Effects & Risks
No human safety data from therapeutic use. Endogenous humanin is naturally present in circulation, suggesting basic tolerability. Theoretical concerns include effects on insulin sensitivity and glucose metabolism, as humanin modulates IGF/insulin signaling pathways. Long-term exogenous administration effects are unknown.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.